Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus chemotherapy followed by two-field versus three-field lymph node dissection in upper thoracic esophageal squamous cell carcinoma
ChiCTR2400080591Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall survival. Started Feb 2024; status: recruiting.
02
Drugs
camrelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400080591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080591.